Abstract #0290

Progressive site-directed therapy for oligo-progressive castration-resistant prostate cancer

Soichiro Yoshida¹, Taro Takahara², Yuki Arita^3,4, Chikako Ishii⁴, Kazuma Toda⁵, Kazuma Toda⁵, Tsuyoshi Sakamoto⁶, Toshiki Kijima¹, Minato Yokoyama¹, Junichiro Ishioka¹, Yoh Matsuoka¹, Kazutaka Saito¹, Ryoichi Yoshimura⁵, and Yasuhisa Fujii¹

¹Urology, Tokyo Medical and Dental University, Tokyo, Japan, ²Biomedical Engineering, Tokai University School of Engineering, Kanagawa, Japan, ³Radiology, Keio University School of Medicine, Tokyo, Japan, ⁴Radiology, Advanced Imaging Center, Yaesu Clinic, Tokyo, Japan, ⁵Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, Japan, ⁶PixSpace, Ltd., Fukuoka, Japan

Locoregional therapy for oligometastatic prostate cancer has generated great interest. However, the benefit for castration-resistant prostate cancer (CRPC) has not been fully demonstrated. According to the current study, whole body-MRI incorporating DWI identified a substantial number of oligo-progressive CRPC patients (OP-CRPC) with a number of progressive lesions 3 or less. Progressive site-directed therapy (PSDT) to OP-CRPC provided a high treatment effect in terms of prostate-specific antigen (PSA) response, especially for patients with longer PSA-doubling time. Furthermore, this study identified the site-dependencies of the PSDT treatment effect; patients whose progressive site was localized in the pelvis were good candidates for PSDT.

This abstract and the presentation materials are available to members only; a login is required.

Join Here